U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Regulatory Information
  3. Search for FDA Guidance Documents
  4. CVM GFI #290 (VICH GL61) – Pharmaceutical Development
  1. Search for FDA Guidance Documents

GUIDANCE DOCUMENT

CVM GFI #290 (VICH GL61) – Pharmaceutical Development May 2024

Download the Draft Guidance Document Read the Federal Register Notice
Draft

Not for implementation. Contains non-binding recommendations.

Docket Number:
FDA-2024-D-1133
Issued by:
Guidance Issuing Office
Center for Veterinary Medicine

This guidance describes the suggested contents for the Pharmaceutical Development section for veterinary medicinal products, which provides an opportunity to present the knowledge gained through the application of scientific approaches and quality risk management to the development of a product and its manufacturing process.  It is first produced for the original marketing application and can be updated to support new knowledge gained over the lifecycle of a product.  

Submit Comments

Submit Comments Online

You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))

If unable to submit comments online, please mail written comments to:

Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852

All written comments should be identified with this document's docket number: FDA-2024-D-1133.

Questions?

Contact Point
Mai Huynh
Center for Veterinary Medicine
Office of New Animal Drug Evaluation
Food and Drug Administration
7500 Standish Place, HFV-140
Rockville, MD 20855
Mai.Huynh@fda.hhs.gov
240-402-0669
Back to Top